£142.02

CRC Press Myelodysplastic Syndromes: Pathobiology and Clinical Management: 36 (Basic and Clinical Oncology)

Price data last checked 54 day(s) ago - refreshing...

View at Amazon

Price History & Forecast

Last 37 days • 37 data points (No recent data available)

Historical
Generating forecast...
£142.02 £130.58 £133.08 £135.57 £138.07 £140.56 £143.06 25 January 2026 03 February 2026 12 February 2026 21 February 2026 02 March 2026

Price Distribution

Price distribution over 37 days • 2 price levels

Days at Price
Current Price
5 days 32 days · current 0 8 16 24 32 £132 £142 Days at Price

Price Analysis

Most common price: £142 (32 days, 86.5%)

Price range: £132 - £142

Price levels: 2 different prices over 37 days

Description

Written by a team of leading authorities in pathogenesis, diagnostic techniques, and clinical management strategies in myelodysplastic syndrome (MDS), this text provides a concise, easy-to-follow review of the advances in the science, classification, diagnosis, and management of the condition. An ideal source for hematologists, oncologists, and cancer researchers, this Second Edition features: a new eight-page color insert 200 color and black-and-white illustrations reworked content organized into three sections: MDS epidemiology and biology; diagnosis, classification, and prognosis; and MDS therapy thoroughly updated chapters reflecting a shift from the topical focus as dictated by the evolution of the field New topics in Myelodysplastic Syndrome include: del(5q) and 5q-syndrome, CMML, and MDS-MPD overlap syndrome the reborn DNA methyltransferase inhibiting nucleoside analogs the diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features the role of mitochondria and the potential importance of iron overload in MDS global genomics approaches, such as cDNA expression arrays, array-based comparative genomic hybridization, and single nucleotide polymorphism array the role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MD other disease-associated alterations, such as abnormalities of B lymphocyte populations in MD three recently approved drugs: azacitidine, lenalidomide, and decitabine

Product Specifications

Format
Hardcover
Domain
Amazon UK
Release Date
12 December 2008
Listed Since
05 November 2007

Barcode

No barcode data available